KUSHKEVYCH, Ivan, Monika VÍTĚZOVÁ, Peter KOLLAR and Josef JAMPILEK. Intestinal sulfate-reducing bacteria under the effect of salicylamides derivatives. In Achievements and prospects of microbiology. Ivan Franko Lviv National Un. Lviv: Ivan Franko Lviv National University, 2016, p. 72-74. ISBN 978-966-919-203-5.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Intestinal sulfate-reducing bacteria under the effect of salicylamides derivatives
Authors KUSHKEVYCH, Ivan (804 Ukraine, belonging to the institution), Monika VÍTĚZOVÁ (203 Czech Republic, belonging to the institution), Peter KOLLAR (203 Czech Republic) and Josef JAMPILEK (203 Czech Republic).
Edition Ivan Franko Lviv National Un. Lviv, Achievements and prospects of microbiology, p. 72-74, 3 pp. 2016.
Publisher Ivan Franko Lviv National University
Other information
Original language English
Type of outcome Proceedings paper
Field of Study 10600 1.6 Biological sciences
Country of publisher Ukraine
Confidentiality degree is not subject to a state or trade secret
Publication form printed version "print"
RIV identification code RIV/00216224:14310/16:00095905
Organization unit Faculty of Science
ISBN 978-966-919-203-5
Keywords in English salicylamides; bowel diseases; ulcerative colitis; sulfate-reducing bacteria
Tags NZ, rivok
Changed by Changed by: Ing. Nicole Zrilić, učo 240776. Changed: 24/3/2018 20:09.
Abstract
Sulfate-reducing bacteria (SRB) are most likely involved in both the initiation and maintenance of the inflammatory bowel disease (IBD), unfortunately present antibacterial chemotherapeutics used in the treatment of IBD have been ineffective. Thus, the antimicrobial activity of salicylamide derivatives on two different genera of intestinal SRB, Desulfovibrio and Desulfomicrobium was investigated. Six 2-(phenylcarbamoyl)phenyl N-[(benzyloxy)carbonyl]alkanoatesand three 2-hydroxy-N-[(2S)-1-oxo-1-(phenylamino)alkan-2-yl]benzamides showed MIC values in the range from 0.22 to 0.35 microM against Desulfovibrio piger Vib-7 and in the range from 0.27 to 8.52 microM against Desulfomicrobium sp. Rod-9, which is by two orders of magnitude lower compared with ciprofloxacin.
PrintDisplayed: 19/6/2024 16:56